Pharvaris N.V. PHVS
31.28 USD -0.38 (-1.20%)
Regular-session close
31.28 0.00 0.00%
After hours · Nov 20, 4:00 PM ET
30.43 Day range 31.99
23.68 52-week range 38.86
- YTD
- +12.72%
- 1 year
- +29.26%
News
zacks.com Wall Street Analysts See a 79.41% Upside in Pharvaris (PHVS): Can the Stock Really Move This High? The mean of analysts' price targets for Pharvaris (PHVS) points to a 79.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among…benzinga.com Pharvaris Q3 EPS $(0.77) Beats $(0.82) Estimate Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.82) by 6.1 percent. This is a 11.59 percent decrease over losses of $(0.69) per…
benzinga.com This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday Analysts upgraded Incyte, Intel, Rivian and Monolithic Power, raising ratings and targets; MPWR’s target increased to $1,700.
benzinga.com This Hilton Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Analysts upgraded VF Corp, Hilton, Ares Capital, eBay and Wintrust Financial, raising targets for VF, Hilton, eBay and Wintrust.
benzinga.com This Pentair Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Wednesday Analysts upgraded Pentair to Neutral with a $65 target and Sun Life Financial to Outperform, raising its target to C$122.
benzinga.com This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday Analysts upgraded SAFE, CNOB, LMT and more.
benzinga.com Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade Bank of America upgrades Pharvaris to Buy with a new price target, citing reduced clinical risk for deucrictibant in hereditary angioedema despite market competition.
benzinga.com This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…benzinga.com B of A Securities Upgrades Pharvaris to Buy, Maintains Price Target to $44 B of A Securities analyst Tazeen Ahmad upgrades Pharvaris (NASDAQ:PHVS) from Neutral to Buy and maintains the price target from $44 to $44.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC)…
